Francis Ellyin, MD
Family Medicine · Las Vegas, NVNPI 1932218096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 310 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,569 and has fallen 53.2% since, to $1,203 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- AstraZeneca$1K
- Novo Nordisk$782
- Johnson & Johnson$777
- Amarin Pharma, Inc.$661
- plus $5K from 28 others
What the payments were for
- Food & beverage$11,14498%
- Education$1321%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $2,107 |
| Amgen | 20 | $1,177 |
| AstraZeneca | 24 | $1,098 |
| Novo Nordisk | 31 | $782 |
| Johnson & Johnson | 8 | $777 |
| Amarin Pharma, Inc. | 44 | $661 |
| Lilly USA, LLC | 29 | $482 |
| Pfizer | 12 | $385 |
| Otsuka America Pharmaceutical, Inc. | 5 | $319 |
| Boehringer Ingelheim | 6 | $316 |
| Esperion Therapeutics, Inc. | 5 | $302 |
| Astellas Pharma US Inc | 5 | $295 |
| Merck | 12 | $287 |
| Gilead | 2 | $252 |
| Phathom Pharmaceuticals, Inc. | 2 | $251 |
| GSK | 6 | $231 |
| E.r. Squibb & Sons, L.L.C. | 3 | $223 |
| Vanda Pharmaceuticals Inc. | 11 | $210 |
| Corcept Therapeutics | 4 | $195 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $150 |
| Abbott | 2 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $105 |
| Boston Scientific | 1 | $100 |
| Kowa Pharmaceuticals America, Inc. | 6 | $99 |
| Mannkind Corporation | 2 | $78 |
| Eisai Inc. | 3 | $62 |
| Currax Pharmaceuticals LLC | 3 | $51 |
| Tactile Systems Technology Inc | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Novartis | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,336 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $97,039 |
| JardianceEmpagliflozin | 41 | $55,358 |
| EliquisApixaban | 27 | $34,153 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,164 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $18,332 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 16 | $16,609 |
| MounjaroTirzepatide | 13 | $13,348 |
| TrulicityDulaglutide | 13 | $12,324 |
| VascepaIcosapent Ethyl | 18 | $9,720 |
| FarxigaDapagliflozin Propanediol | 16 | $9,699 |
| SynthroidLevothyroxine Sodium | 38 | $4,321 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $2,880 |
| Atorvastatin Calcium | 266 | $2,583 |
| Nebivolol Hcl | 16 | $1,755 |
| Levothyroxine Sodium | 155 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $782 | $97,03977 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $316 | $71,96757 claims |
| PfizerEliquis | $385 | $34,15327 claims |
| Lilly USA, LLCMounjaro, Trulicity | $482 | $25,67226 claims |
| GSKTrelegy Ellipta | $231 | $20,16423 claims |
| MerckJanumet | $287 | $18,33217 claims |
| AstraZenecaFarxiga | $1,098 | $9,69916 claims |
| AbbVieSynthroid | $2,107 | $4,32138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.